ABSTRACT
Forty-two children, all over one year of age, were given vincristine, cyclophosphamide, and sequentially timed cisplatin and VM-26 (OPEC) or OPEC and doxorubicin (OPEC-D) as initial treatment for newly diagnosed stage III or IV neuroblastoma. Good partial response was achieved in 31 patients (74%) overall and in 28 (78%) of 36 patients whose treatment adhered to the chemotherapy protocol, compared with a 65% response rate achieved in a previous series of children treated with pulsed cyclophosphamide and vincristine with or without doxorubicin. Only six patients, including two of the six children whose treatment did not adhere to protocol, failed to respond, but there were five early deaths from treatment-related complications. Tumor response to OPEC, which was the less toxic of the two regimens, was at least as good as tumor response to OPEC-D. Cisplatin-induced morbidity was clinically significant in only one patient and was avoided in others by careful monitoring of glomerular filtration rate and hearing. Other centers should test the efficacy of OPEC or equivalent regimens in the treatment of advanced neuroblastoma.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Neuroblastoma/drug therapy , Adolescent , Adult , Age Factors , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Child , Child, Preschool , Cisplatin/administration & dosage , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Humans , Infant , Neoplasm Staging , Neuroblastoma/pathology , Prognosis , Teniposide/administration & dosage , Vincristine/administration & dosageABSTRACT
Primary hepatic tumours in children represent an heterogeneous group of neoplasms. Malignant tumours are more common (60% of primary liver tumours), but account for only 1.2-5% of all paediatric neoplasms. There are two main types of malignant tumour, those of epithelial origin, hepatoblastoma (HB) and hepatocellular carcinoma (HCC), and the rarer mesenchymal tumours, e.g. rhabdomyosarcoma and undifferentiated sarcoma, (Weinberg AG, Finegold, MJ. Primary hepatic tumours of childhood. Hum Pathol 1983, 14, 512-532). Vascular tumours e.g. haemangioendotheliomas are the most common of the benign tumours followed by mesenchymal hamartoma and the rare hepatic adenoma and focal nodular hyperplasia. This article will concentrate on the malignant epithelial tumours.
Subject(s)
Carcinoma, Hepatocellular/drug therapy , Hepatoblastoma/drug therapy , Liver Neoplasms/drug therapy , Carcinoma, Hepatocellular/etiology , Carcinoma, Hepatocellular/pathology , Forecasting , Hepatoblastoma/etiology , Hepatoblastoma/pathology , Humans , Liver Neoplasms/etiology , Liver Neoplasms/pathology , Neoplasm Staging , Prognosis , Survival AnalysisABSTRACT
The histopathological features of hepatoblastoma in 17 patients treated with preoperative chemotherapy were compared with those in 11 patients not subjected to chemotherapy during the same 11-year period. Tumor necrosis was more extensive in patients receiving preoperative chemotherapy. Two tumors, however, were apparently unaffected by chemotherapy. There was no obvious correlation between the extent of necrosis and the number of courses of chemotherapy. There also seems to be no evidence of preferential ablation of a particular morphological type of tumor. The most notable feature in cases treated with chemotherapy was the extensive presence of osteoid. Osteoid was present in 36% of untreated cases, occupying < 5% of the surface area, compared with 82% in the treated group. In seven cases, osteoid occupied > 40% of the surface area. This finding raises speculation about the role of chemotherapy in the maturation of tumors that have an inherent ability to differentiate. A long-term study is needed to clarify the prognostic significance of mature heterologous elements in hepatoblastoma.
Subject(s)
Hepatoblastoma/drug therapy , Hepatoblastoma/pathology , Liver Neoplasms/drug therapy , Liver Neoplasms/pathology , Adolescent , Child , Child, Preschool , Cisplatin/therapeutic use , Doxorubicin/therapeutic use , Female , Hepatoblastoma/surgery , Humans , Infant , Infant, Newborn , Liver Neoplasms/surgery , Male , Postoperative PeriodABSTRACT
The aims of this study were as follows. (1) To demonstrate the spectrum, frequency and changes on follow-up of sonographic abnormalities in the thyroid gland of survivors of Hodgkin's disease who had received radiotherapy to the neck in childhood. (2) To compare the sonographic findings with clinical examination and radionuclide imaging. (3) To investigate the association between the presence or absence of focal sonographic abnormalities with age at radiotherapy, the interval from radiotherapy, the presence of a raised thyroid stimulating hormone (TSH) and the length of time the TSH had been raised. 46 patients were scanned prospectively and rescanned at 6-18 months. The mean age at first sonography was 22.7 years, the median age at radiotherapy was 12.5 years, and the median interval post-radiation was 10.3 years. Sonographic abnormalities were seen in all 46 patients. 45 had diffuse atrophy and 30 had focal sonographic abnormalities. 18 patients developed new focal sonographic abnormalities on follow-up. Focal sonographic abnormalities were more commonly associated with longer duration of a raised TSH. Two patients had thyroid carcinoma. Sonographic abnormalities of the thyroid are common in patients following neck radiotherapy in childhood. Focal abnormalities are usually associated with a longer duration of raised TSH.
Subject(s)
Hodgkin Disease/radiotherapy , Radiation Injuries/diagnostic imaging , Thyroid Diseases/diagnostic imaging , Thyroid Gland/diagnostic imaging , Adolescent , Adult , Age Factors , Child , Female , Follow-Up Studies , Humans , Male , Prospective Studies , Radiation Injuries/blood , Radiation Injuries/etiology , Radiotherapy/adverse effects , Survivors , Thyroid Diseases/blood , Thyroid Diseases/etiology , Thyroid Gland/radiation effects , Thyroid Nodule/diagnostic imaging , Thyrotropin/blood , Time Factors , UltrasonographyABSTRACT
Two infants with familial erythrophagocytic reticulosis attained a durable complete remission after combination chemotherapy including intrathecal methotrexate. Though both later died, neither child had definitive evidence of tumour at necropsy.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphatic Diseases/genetics , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Female , Humans , Infant , Lymphatic Diseases/drug therapy , Male , Phagocytosis , Prednisone/administration & dosage , Vincristine/administration & dosageABSTRACT
Patients who receive radiotherapy to the neck are at risk of developing thyroid dysfunction. This prospective study of patients whose treatment for Hodgkin's disease in childhood included radiotherapy to the neck aimed to investigate the incidence and natural history of thyroid dysfunction and the morphological changes of the gland demonstrated on ultrasound. Forty-seven patients were investigated by clinical examination, thyroid function tests and thyroid ultrasound. Only six patients had a clinically detectable abnormality, but 64% had abnormal thyroid function tests. All patients had an abnormal thyroid ultrasound scan and 42% had at least one focal abnormality. A significant association was found between the presence of a focal lesion on ultrasound and young age at radiotherapy, longer follow-up and the length of time that the thyroid-stimulating hormone (TSH) level had been elevated. During follow-up, 65% of patients not on thyroxine developed new focal abnormalities. The longest time interval between radiotherapy and an increase in TSH level was 94 months, and from radiotherapy to the appearance of a focal abnormality on thyroid ultrasound was over 18 years. Three patients were found to have a thyroid carcinoma. These findings indicate the importance of long-term follow-up for patients treated by neck irradiation for Hodgkin's disease in childhood.
Subject(s)
Head and Neck Neoplasms/radiotherapy , Hodgkin Disease/radiotherapy , Radiation Injuries/etiology , Thyroid Nodule/etiology , Adolescent , Biopsy, Needle , Child , Child, Preschool , Dose-Response Relationship, Radiation , Female , Follow-Up Studies , Humans , Male , Neck/radiation effects , Prospective Studies , Radiation Injuries/diagnostic imaging , Radiation Injuries/pathology , Radiation Injuries/surgery , Radionuclide Imaging , Radiotherapy/adverse effects , Thyroid Gland/radiation effects , Thyroid Nodule/diagnostic imaging , Thyroid Nodule/surgery , Thyroxine/therapeutic useABSTRACT
Testicular function was studied in 40 males treated in childhood for Hodgkin's disease at St Bartholomew's Hospital, and the Hospital for Sick Children, London, between 1971-1985. All patients were 16 years or over at evaluation, and off treatment more than 6 years. Basal FSH, LH and testosterone levels were measured. Testicular size was measured using a Prader orchidometer, and all patients were offered a seminal analysis. Twenty-eight patients were treated with chemotherapy, usually ChlVPP. Twenty-one also had radiotherapy, five below the diaphragm. Twelve patients were treated with radiotherapy alone (five below the diaphragm). Twenty-six of 28 patients treated with chemotherapy and three of five patients treated with radiotherapy alone below the diaphragm have elevated basal FSH levels, and 18 of these also have elevated basal LH levels. Median testicular volume is 11 ml (range 5-25 ml). Eleven of 13 patients investigated are azoospermic. All patients have normal testosterone levels, and normal secondary sexual characteristics. There is no biochemical evidence of healing of the damaged germinal epithelium with elevated FSH levels persisting up to 17 years from the end of therapy. These results indicate a high incidence of damage to the germinal epithelium in patients treated with ChlVPP chemotherapy and/or radiotherapy below the diaphragm. Appropriate counselling of these patients with regard to their reproductive capabilities is essential.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Hodgkin Disease , Infertility, Male/etiology , Radiotherapy, High-Energy/adverse effects , Testis/physiopathology , Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chlorambucil/administration & dosage , Chlorambucil/adverse effects , Combined Modality Therapy/adverse effects , Follicle Stimulating Hormone/blood , Hodgkin Disease/drug therapy , Hodgkin Disease/radiotherapy , Humans , Infertility, Male/chemically induced , Luteinizing Hormone/blood , Male , Oligospermia/chemically induced , Oligospermia/etiology , Prednisolone/administration & dosage , Prednisolone/adverse effects , Procarbazine/administration & dosage , Procarbazine/adverse effects , Spermatogenesis/drug effects , Spermatogenesis/radiation effects , Testis/drug effects , Testis/radiation effects , Testosterone/blood , Vinblastine/administration & dosage , Vinblastine/adverse effectsABSTRACT
PURPOSE: To determine the prevalence and severity of asymptomatic carotid arterial disease in young patients following neck radiation therapy for Hodgkin lymphoma and to compare the prevalence of carotid arterial disease following radiation therapy alone with that following radiation therapy and chemotherapy. MATERIALS AND METHODS: Forty-two survivors of childhood or early adult Hodgkin lymphoma aged 18-37 years who had undergone radiation therapy more than 5 years earlier underwent carotid arterial ultrasonography. Common carotid intima-media thickness was measured; carotid vessels were assessed for intima-media abnormalities. Results were compared with those from 33 control subjects. RESULTS: Patients had a significantly greater number of abnormal scans than did control subjects (11 [26%] vs one [3%]; P < .01). Ten patients (24%) had intima-media abnormalities that did not cause significant stenosis; one patient had diffuse bilateral intima-media thickening (mean, 1.99 mm) with greater than 70% stenosis of both common carotid arteries. Intima-media thickness was significantly greater in patients (0.51 mm) than in control subjects (0.43 mm; P < .005). The number of abnormalities in patients with radiation therapy plus chemotherapy (six [19%] of 31 patients) did not differ significantly from the number in patients with only radiation therapy (five [45%] of 11 patients; P = .12); there was no significant difference between median intima-media thicknesses (0.50 mm vs 0.51 mm, P > .2). CONCLUSION: Asymptomatic carotid arterial disease occurs frequently in young patients following neck radiation therapy for Hodgkin lymphoma. No difference in prevalence was shown between only radiation therapy and radiation therapy plus chemotherapy.
Subject(s)
Carotid Artery Diseases/diagnostic imaging , Carotid Artery Diseases/etiology , Hodgkin Disease/radiotherapy , Radiation Injuries/diagnostic imaging , Adolescent , Adult , Biopsy , Carotid Arteries/diagnostic imaging , Carotid Arteries/pathology , Carotid Arteries/radiation effects , Carotid Artery Diseases/pathology , Female , Humans , Male , Neck/radiation effects , Radiotherapy/adverse effects , Radiotherapy Dosage , Tunica Intima/diagnostic imaging , Tunica Intima/pathology , Tunica Intima/radiation effects , Tunica Media/diagnostic imaging , Tunica Media/pathology , Tunica Media/radiation effects , UltrasonographyABSTRACT
Between 1981 and 1993, 41 children were treated for hepatoblastoma. Clinical, radiological and pathological data were reviewed retrospectively, focusing on surgical aspects of treatment and outcome. Fourteen children underwent primary resection of the hepatic tumour. One infant with severe congenital anomalies received only palliative treatment. Of 26 with irresectable disease, pulsed cytotoxic chemotherapy (cisplatin and doxorubicin) enabled subsequent surgical excision in 22 and one child with persistent extensive intrahepatic disease was successfully treated by liver transplantation. Thus, with a policy of selective preoperative chemotherapy, 90 per cent of hepatoblastomas were resectable. There were no perioperative deaths from haemorrhage but one child died from an intraoperative tumour embolus. A total of 28 survivors, 27 of whom are disease-free, were followed for a median of 5 years. The cumulative probability of survival in patients treated with intent to cure was 67 per cent. Analysis of survival data suggested a favourable outcome for those with a pure fetal histological tumour subtype. These results demonstrate significant progress in the treatment of hepatoblastoma.